(PharmaNewsWire.Com, January 07, 2017 ) Wilson disease is a rare autosomal recessive inherited disorder of copper metabolism that is characterized by excessive deposition of copper in the liver, brain, and other tissues. Symptoms include abdominal pain, jaundice, problems with speech, swallowing and muscle stiffness. Treatment includes chelators and Vitamin E supplements.
Report Highlights
The Wilson Disease (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Wilson Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Wilson Disease (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Wilson Disease (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Wilson Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Wilson Disease (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Wilson Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Wilson Disease (Central Nervous System)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Wilson Disease (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Wilson Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Number of Products under Development for Wilson Disease, H2 2016 7 Number of Products under Development for Wilson Disease - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Wilson Disease - Pipeline by Dimension Therapeutics Inc, H2 2016 15 Wilson Disease - Pipeline by GMP-Orphan SAS, H2 2016 16 Wilson Disease - Pipeline by Revive Therapeutics Ltd, H2 2016 17 Wilson Disease - Pipeline by Wilson Therapeutics AB, H2 2016 18 Assessment by Monotherapy Products, H2 2016 19
List of Figures
Number of Products under Development for Wilson Disease, H2 2016 7 Number of Products under Development for Wilson Disease - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Products, H2 2016 12 Assessment by Monotherapy Products, H2 2016 19 Number of Products by Targets, H2 2016 20 Number of Products by Stage and Targets, H2 2016 20 Number of Products by Mechanism of Actions, H2 2016 22 Number of Products by Stage and Mechanism of Actions, H2 2016 22 Number of Products by Molecule Types, H2 2016 25 Number of Products by Stage and Molecule Types, H2 2016 25
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
